ArticleCardiology and therapy2024

Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease.

Laszlo A Groh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.